Literature DB >> 36173462

High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD).

Lizong Wang1, Yi Cao2, Wei Guo2, Jingyun Xu3.   

Abstract

BACKGROUND: Cuproptosis induced by FDX1 is a newly discovered mechanism regulating cell death. However, the role of FDX1 in the pathogenesis of colon adenocarcinoma (COAD) remains to be studied.
METHODS: FDX1 expression was analyzed with The Cancer Genome Atlas (TCGA) database and Human Protein Atlas (HPA) database. Association between FDX1 expression and COAD prognosis was investigated via the Kaplan-Meier (KM) survival curve. The differentially expressed genes (DEGs) of FDX1 were screened with R packages and the PPI were constructed via STRING database. Cytoscape software was used to detect the most profound modules in the PPIs network. CancerSEA database was used to analyze the effect of FDX1 expression levels on different functional status of COAD cells. The relationship between FDX1 expression and immune infiltration of COAD was analyzed by TIMER2.0 database. The COAD patients with high expression of FDX1 by Western blot, and the levels of immune infiltration were measured by flow cytometry.
RESULTS: FDX1 was low expressed in most cancers, such as BRCA, KICH, and COAD. The overall survival (OS) and disease-specific survival (DSS) of COAD with high FDX1 expression were better than that of the low expression group. GO-KEGG enrichment analysis revealed that FDX1 and its co-expressed genes played an important role in the pathogenesis of COAD. Moreover, FDX1 expression in COAD were positively associated with "quiescence" and "inflammation" but negatively correlated with "invasion". FDX1 expression was positively correlated with infiltration levels of CD8+ T cells, NK cells, and neutrophils. Oppositely, FDX1 expression was negatively correlated with that of CD4+ T cells and cancer-associated fibroblasts (CAFs). Finally, 6 COAD patients with high expression of FDX1 were screened, and the proportion of CD8+ T cells in cancer tissues of these patients was significantly higher than that in paracancerous, while the CD4+ T cells presented the opposite pattern.
CONCLUSION: FDX1 plays a role in inducing cuproptosis and modulating tumor immunity, which could be considered as potential therapeutic targets in COAD.
© 2022. The Author(s).

Entities:  

Keywords:  COAD; Cuproptosis; FDX1; Immune infiltrate; Prognosis

Year:  2022        PMID: 36173462     DOI: 10.1007/s00432-022-04382-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  39 in total

Review 1.  Progress and future direction in the management of advanced colorectal cancer.

Authors:  K G M Brown; M J Solomon
Journal:  Br J Surg       Date:  2018-05       Impact factor: 6.939

2.  Lipocalin-2 inhibits pancreatic cancer stemness via the AKT/c-Jun pathway.

Authors:  Peipei Hao; Jiamin Zhang; Shu Fang; Miaomiao Jia; Xian Xian; Sinan Yan; Yunpeng Wang; Qian Ren; Fengming Yue; Huixian Cui
Journal:  Hum Cell       Date:  2022-07-06       Impact factor: 4.374

3.  Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes.

Authors:  Firas Baidoun; Kholoud Elshiwy; Yasmine Elkeraie; Zahi Merjaneh; George Khoudari; Muhammad Talal Sarmini; Mohamed Gad; Muneer Al-Husseini; Anas Saad
Journal:  Curr Drug Targets       Date:  2021       Impact factor: 3.465

4.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

Review 5.  Colorectal cancer.

Authors:  Hermann Brenner; Matthias Kloor; Christian Peter Pox
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

6.  Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma.

Authors:  Matthew F Buas; Qianchuan He; Lisa G Johnson; Lynn Onstad; David M Levine; Aaron P Thrift; Puya Gharahkhani; Claire Palles; Jesper Lagergren; Rebecca C Fitzgerald; Weimin Ye; Carlos Caldas; Nigel C Bird; Nicholas J Shaheen; Leslie Bernstein; Marilie D Gammon; Anna H Wu; Laura J Hardie; Paul D Pharoah; Geoffrey Liu; Prassad Iyer; Douglas A Corley; Harvey A Risch; Wong-Ho Chow; Hans Prenen; Laura Chegwidden; Sharon Love; Stephen Attwood; Paul Moayyedi; David MacDonald; Rebecca Harrison; Peter Watson; Hugh Barr; John deCaestecker; Ian Tomlinson; Janusz Jankowski; David C Whiteman; Stuart MacGregor; Thomas L Vaughan; Margaret M Madeleine
Journal:  Gut       Date:  2016-08-02       Impact factor: 23.059

7.  Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Authors:  Frederick Arce Vargas; Andrew J S Furness; Isabelle Solomon; Kroopa Joshi; Leila Mekkaoui; Marta H Lesko; Enrique Miranda Rota; Rony Dahan; Andrew Georgiou; Anna Sledzinska; Assma Ben Aissa; Dafne Franz; Mariana Werner Sunderland; Yien Ning Sophia Wong; Jake Y Henry; Tim O'Brien; David Nicol; Ben Challacombe; Stephen A Beers; Samra Turajlic; Martin Gore; James Larkin; Charles Swanton; Kerry A Chester; Martin Pule; Jeffrey V Ravetch; Teresa Marafioti; Karl S Peggs; Sergio A Quezada
Journal:  Immunity       Date:  2017-04-11       Impact factor: 31.745

8.  GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation.

Authors:  Hongda Ding; Xixia Zhang; Yang Su; Changjun Jia; Chaoliu Dai
Journal:  Cell Mol Biol Lett       Date:  2020-02-24       Impact factor: 5.787

9.  Decreased expression of MT1E is a potential biomarker of prostate cancer progression.

Authors:  Rita Demidenko; Kristina Daniunaite; Arnas Bakavicius; Rasa Sabaliauskaite; Aiste Skeberdyte; Donatas Petroska; Arvydas Laurinavicius; Feliksas Jankevicius; Juozas R Lazutka; Sonata Jarmalaite
Journal:  Oncotarget       Date:  2017-06-27

10.  Modulation of anti-tumor immunity by the brain's reward system.

Authors:  Tamar L Ben-Shaanan; Maya Schiller; Hilla Azulay-Debby; Ben Korin; Nadia Boshnak; Tamar Koren; Maria Krot; Jivan Shakya; Michal A Rahat; Fahed Hakim; Asya Rolls
Journal:  Nat Commun       Date:  2018-07-13       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.